Antitrust Law Daily Wrap Up, FRANCHISING & DISTRIBUTION—S.D.N.Y.: Fraud claims fail in dispute over pharmaceutical distribution agreement, (Jul 6, 2026)

By Patricia K. Ruiz, J.D.

The court found alter-ego allegations and misrepresentation claims inadequately pleaded.

The federal district court in New York City dismissed all claims against the sole owner of pharmaceutical distributor Lifsa Drugs LLC and threw out ANI Pharmaceuticals Inc.’s fraudulent inducement and negligent misrepresentation claims, holding that ANI failed to plausibly allege an alter-ego relationship sufficient to establish personal jurisdiction and did not satisfy the heightened pleading standards governing fraud-based claims. The court found ANI’s allegations of corporate domination were largely conclusory and that the complaint did not explain with particularity how the challenged statements regarding Lifsa’s sales and finances were false. The ruling leaves only ANI’s breach-of-contract claims against Lifsa pending (ANI Pharmaceuticals, Inc. v. Lifsa Drugs LLC, No. 1:25-cv-09227-JMF (S.D.N.Y. Jul. 1, 2026)).

Background. ANI sued Lifsa and its principal, Rajesh M. Kumar, over a March 2022 supply and distribution agreement under which Lifsa became the exclusive U.S. distributor of two ANI pharmaceutical products. ANI alleged that Kumar misrepresented Lifsa’s financial condition and sales performance during pre-contract negotiations, inducing ANI to enter the agreement. The complaint asserted breach-of-contract, fraudulent inducement and negligent misrepresentation claims and sought to hold Kumar liable as Lifsa’s alter ego.

The agreement contained a forum-selection clause requiring disputes to be litigated in New York courts. Kumar signed the agreement only in his representative capacity as Lifsa’s chief executive. Defendants moved to dismiss the claims against Kumar for lack of personal jurisdiction and sought dismissal of the tort claims and alter-ego allegations for failure to state a claim.

Personal jurisdiction. Although Lifsa did not dispute that it had consented to jurisdiction through the forum-selection clause, the court held that the clause did not automatically extend to Kumar as a nonsignatory acting only in a representative capacity. As a result, ANI was required to plausibly allege that Kumar and Lifsa were alter egos.

Alter-ego allegations. The court concluded that ANI had not met that burden. ANI alleged that Kumar was Lifsa’s sole member, officer and employee, that Lifsa operated from Kumar’s home without paying rent, that the company was undercapitalized, and that Kumar commingled company and personal assets. The court held that common ownership and use of a home office, without more, were insufficient to establish domination and control and found the remaining allegations unsupported by specific facts. ANI, the court said, failed to allege facts showing inadequate capitalization, disregard of corporate formalities or actual commingling of funds and assets. Because ANI did not plausibly allege an alter-ego relationship, the court held that it lacked personal jurisdiction over Kumar and dismissed all claims against him.

Choice of law and pleading standard. Turning to the tort claims against Lifsa, the court applied New York law to the fraudulent inducement claim and New Jersey law to the negligent misrepresentation claim. Nevertheless, it held that both claims were subject to Federal Rule of Civil Procedure 9(b)’s heightened pleading standard because they were based on allegations that Lifsa knowingly deceived ANI during contract negotiations.

Alleged misrepresentations. ANI relied principally on a January 2022 email in which Kumar referred collectively to Lifsa and another entity and stated that “my company” had gross annual sales exceeding $65 million, as well as materials presented during a February 2022 meeting, including a PowerPoint presentation showing actual and projected sales figures. ANI alleged that Kumar improperly inflated Lifsa’s sales by including sales generated by another company he controlled.

Falsity. The court found those allegations insufficient. It held that the complaint did not explain how the cited sales figures were false, how they allegedly included sales from another entity, or how Lifsa’s reported sales had otherwise been inflated. The court also found that allegations concerning a bank statement and other financial information shown during the meeting failed to satisfy Rule 9(b) because the complaint did not identify any specific fraudulent statements contained in those materials.

Fraudulent intent. The court further held that ANI failed to plead facts giving rise to a strong inference of fraudulent intent. According to the court, the complaint alleged only a generalized desire to profit from a business relationship with ANI, which was insufficient to establish motive to commit fraud. The court also found no strong circumstantial evidence of conscious misbehavior or recklessness.

Additional allegations. ANI attempted to bolster its allegations through facts raised in its opposition brief, including assertions regarding the history and ownership of the other company referenced in Kumar’s communications. The court declined to consider those assertions, stating that parties may not amend pleadings through motion papers. The court added that even if those allegations were considered, they would not cure the complaint’s deficiencies because ANI had not alleged reliance on those specific representations when entering the agreement.

Disposition. The court granted the motion to dismiss all claims against Kumar for lack of personal jurisdiction and dismissed ANI’s fraudulent inducement and negligent misrepresentation claims against Lifsa for failure to state a claim. The court also declined to grant leave to amend sua sponte, noting that ANI had not requested leave to amend, had not identified facts that would cure the deficiencies and had previously been given an opportunity to amend its pleading.

The Case is No. 1:25-cv-09227-JMF.

Judge: Furman, J.

Attorneys: Nicole G. McDonough (Sills Cummis & Gross PC) for ANI Pharmaceuticals, Inc. Gerald William Griffin (Carter Ledyard & Milburn LLP) for Lifsa Drugs, LLC.

Companies: ANI Pharmaceuticals, Inc.; Lifsa Drugs, LLC

Cases: FranchisingDistribution NewYorkNews